Bi­par­ti­san group of sen­a­tors seeks to elim­i­nate in­ter­change­abil­i­ty des­ig­na­tion for biosim­i­lars

The US biosim­i­lar mar­ket has al­ways been dis­tinct from the EU mar­ket, par­tic­u­lar­ly when it comes to the des­ig­na­tion of cer­tain biosim­i­lars as be­ing in­ter­change­able …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER